+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 40 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting an observational study to understand the short-term progression of geographic atrophy GA caused by age-related macular degeneration AMD in adults aged 55 and older. The goal is to identify participants with progressive GA and measure structural and functional changes, while exploring possible links to genetic and lifestyle factors. Participants will not receive any investigational treatments during this non-interventional study. Instead, their condition will be closely monitored over time using imaging techniques such as fundus autofluorescence FAF and optical coherence tomography OCT. The study will include assessments at baseline, month 3, and month 6 to track GA progression and related changes. Throughout the study, participants will undergo various eye examinations including visual acuity tests and microperimetry to measure retinal sensitivity. Researchers will collect data on GA progression and analyze correlations with genetic and lifestyle aspects. The study aims to provide detailed insight into GA changes over six months, with safety and adherence monitored by the research team. Participation will last approximately six months with scheduled visits for assessments.

Age: 55Years +All Genders
19 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
E

Actively Recruiting

Researchers are evaluating how well elritercept works to improve anemia in adults with myelofibrosis MF who are already taking ruxolitinib. The study compares elritercept to a placebo and aims to learn if elritercept reduces tiredness, improves symptoms related to MF, helps participants be more active, and impacts the bone marrow and spleen. The safety of elritercept is also being assessed over a long period. This is a Phase 3, double-blind, randomized trial sponsored by Takeda. Participants will receive either elritercept or a matching placebo as a subcutaneous injection every 4 weeks for approximately 36 weeks during the double-blinded treatment period. Elritercept starts at a dose of 3.75 mgkg, with a possible increase to 5.0 mgkg from the third cycle based on response and safety. After this period, those on placebo may switch to elritercept during an extended open-label phase where dosing adjustments are also possible. During the study, participants will be monitored regularly with assessments including blood transfusion independence, fatigue levels, symptom scores, spleen size by imaging, and development of antibodies to the study drug. Researchers will track safety and overall survival for up to seven years. Participants can expect visits every 4 weeks during treatment, and the study includes long-term follow-up to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 3
195 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and preliminary efficacy of CTx001, a genetic therapy given via a single subretinal injection, in people with geographic atrophy GA caused by age-related macular degeneration AMD. This first in human Phase 12 study aims to determine how well CTx001 works and how safe it is for this eye condition. Participants will receive one of three dose levels of CTx001 in sequential cohorts. After the initial dosing, some participants may enter expansion phases with selected doses. The treatment is given once by subretinal injection, and safety and efficacy are monitored regularly up to 2 years. Long-term safety follow-up continues annually for up to 5 years after dosing. During the study, participants will undergo regular assessments including imaging to measure lesion size and retinal function, visual acuity tests, and evaluations of retinal sensitivity. Researchers will monitor safety and immune responses to the therapy. The primary outcome focuses on safety and tolerability through the first year, while secondary outcomes assess changes in the eyes structure and function for up to 2 years and long-term safety for 5 years. Total participation may last up to 5 years.

Age: 55Years +All GendersPhase 1Phase 2
8 locations
C

Actively Recruiting

Researchers are studying severe diabetic macular oedema DMO, a condition where fluid builds up in the central part of the retina called the macula, leading to vision loss. The study compares two treatments for people with diabetes who have severe DMO, defined by a thickened macula of 400 microns or more. The goal is to find out if starting with anti-VEGF injections followed by subthreshold micropulse laser SML treatment when the macula thickness decreases below 400 microns is as effective and more cost-effective than continuing anti-VEGF injections alone. Participants are randomly assigned to one of two groups one receives anti-VEGF injections alone, which are given monthly at first and then every 1 to 3 months as needed the other group starts with anti-VEGF injections and switches to SML treatment every 2 to 3 months once the macula thickness is less than 400 microns. The anti-VEGF drugs used include ranibizumab, aflibercept, faricimab, and brolucizumab, and SML is a laser procedure that does not damage the macula. Treatment continues until the diabetic macular oedema clears. During the study, participants attend regular clinic visits for eye exams including optical coherence tomography OCT scans to measure macula thickness and vision tests to assess best-corrected visual acuity BCVA. Researchers also collect data on quality of life, safety, treatment use, and participant experiences. The primary outcome is vision measured at 104 weeks after randomisation. The study lasts about two years, with ongoing monitoring of treatment effects, side effects, and participant satisfaction to assess the potential for wider use of the combined treatment approach.

Age: 18Years +All GendersPhase 3
22 locations
S

Actively Recruiting

Healthy Volunteer

This observational study focuses on children and teenagers aged 2 to 16 years, investigating the normal appearances of lymph nodes in the lower abdomen using point of care ultrasound POCUS. The goal is to better understand what normal lymph node numbers and sizes look like in young people who visit the pediatric emergency department for non-abdominal injuries. This information aims to help in identifying abnormalities such as mesenteric adenitis, a condition often suspected but not well-defined by imaging. Participants include children presenting with injuries like head, face, neck, or limb trauma but without abdominal or infectious symptoms. The study uses POCUS to scan the right lower abdomen to record the number and size of lymph nodes. This baseline evaluation will help define normal ranges to support future diagnosis of mesenteric adenitis. During the study, participants undergo abdominal ultrasound scans, with data collected over a six-month period to measure lymph nodes. Researchers will monitor the ultrasound results to describe normal lymph node characteristics. There are no treatments involved, and participation mainly includes one or more ultrasound assessments to gather these measurements safely and non-invasively.

Age: 2Years - 16YearsAll Genders
1 location
P

Actively Recruiting

This trial investigates treatment options for adults aged 16 to 69 with early-stage classical Hodgkin lymphoma, specifically stage I or II supradiaphragmatic disease without mediastinal bulk or B symptoms. The study compares two chemotherapy regimens ABVD and A2VD, using a PET response-adapted design to adjust therapy based on treatment response. It is a phase III, randomized, open-label trial conducted internationally and sponsored by University College London and Canadian Cancer Trials Group. Participants will be randomly assigned to receive either ABVD chemotherapy doxorubicin, bleomycin, vinblastine, and dacarbazine or A2VD chemotherapy doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine with growth factor support. After two 28-day cycles, a PET-CT scan will assess response using the Deauville score to guide further treatment. Patients with scores 1-3 receive one more cycle those with score 4 receive two more cycles followed by involved site radiotherapy patients with score 5 discontinue trial treatment and receive alternative therapy as determined by their clinician. Throughout the study, participants undergo PET-CT scans and clinical assessments to monitor treatment response and safety. They will be followed for at least five years post-treatment to evaluate progression-free survival and other outcomes such as event-free survival, overall survival, and incidence of second cancers or cardiovascular disease. Safety and toxicity are monitored from treatment start until 30 days after completion. The overall study period extends until 2032.

Age: 16Years - 69YearsAll GendersPhase 3
72 locations

1-10 of 40

1